[1] Article Title: Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review
	•	Line(s): 1
	•	Section: Title Page
	•	Quote(s): “Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review”

⸻

[2] Publication Year: 2024
	•	Line(s): 9
	•	Section: Title Page
	•	Quote(s): “Published online: October 9, 2024”

⸻

[3] Region: Global (includes North America, Europe, Asia, Oceania, Africa)
	•	Line(s): 142–150
	•	Section: Results
	•	Quote(s): “There was a wide geographical distribution, with representation of all continents… A total of 63 studies were performed in Europe… Only two studies were performed in Africa and Oceania.”

⸻

[4] Country: Multiple (including Italy, UK, Norway, USA, Japan, Netherlands, Greece, South Africa)
	•	Line(s): 142–150
	•	Section: Results
	•	Quote(s): “A total of 63 studies were performed in Europe with particular contributions from Italy (13 studies), the UK (7 studies), and Norway (7 studies).”

⸻

[5] Coverage Area: International
	•	Line(s): 14–20
	•	Section: Abstract / Introduction
	•	Quote(s): “This systematic review aimed to estimate the prevalence, incidence, and mortality of all MG types and myasthenic syndromes worldwide.”

⸻

[6] Study Design: Systematic Review
	•	Line(s): 2, 14
	•	Section: Title Page / Abstract
	•	Quote(s): “Systematic Review” / “This systematic review aimed to…”

⸻

[7] Study Population: Patients with Myasthenia Gravis or Myasthenic Syndromes
	•	Line(s): 91–94
	•	Section: Methods
	•	Quote(s): “studies enrolling subjects with a clinical diagnosis of MG or myasthenic syndromes or any other type of MG subgroup”

⸻

[8] Population Characteristics: Mixed age groups, both sexes; adult mean age 53.7 years; juvenile subgroup present
	•	Line(s): 255–273
	•	Section: Age and Sex Distribution
	•	Quote(s): “The mean age of ALL MG cases was 53.7 years (range: 25–74.9)… females experienced an onset… earlier than males… juvenile MG… PR of 45.6 per million…”

⸻

[9] Data Source Type: Literature
	•	Line(s): 158–160
	•	Section: Quality Assessment
	•	Quote(s): “employed national health registries/databases… subjects enrolled by clinical records”

⸻

[10] Data Source Details:
	•	Line(s): 158–160
	•	Section: Quality Assessment
	•	Quote(s): “employed national health registries/databases… Hospital records rarely include patients with mild symptoms…”

⸻

[11] Study Timeline Type: NR
	•	Line(s): 157–158
	•	Section: Quality Assessment
	•	Quote(s): “Most of the included studies (86.2%) were retrospective…”

⸻

[12] Number of Sites: NR
	•	Line(s): 137–140
	•	Section: Results
	•	Quote(s): “Overall, 94 studies were included…”

⸻

[13] Study Start Year: 1952 (earliest literature)
	•	Line(s): 135
	•	Section: Abstract
	•	Quote(s): “A total of 94 studies, performed between 1952 and 2022…”

⸻

[14] Study End Year: 2022 (latest literature)
	•	Line(s): 135
	•	Section: Abstract
	•	Quote(s): “A total of 94 studies, performed between 1952 and 2022…”

⸻

[15] Main Ethnicity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[16] Ethnicity Details: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[17] Disease Studied: Myasthenia Gravis (MG) and Myasthenic Syndromes including LEMS
	•	Line(s): 1, 14–15
	•	Section: Title / Abstract
	•	Quote(s): “Myasthenia Gravis and Myasthenic Syndromes… including… Lambert-Eaton Myasthenic Syndrome (LEMS)”

⸻

[18] Diagnosis Method: NA
	•	Line(s): 91–94, 30–34
	•	Section: Methods / Introduction
	•	Quote(s): “studies enrolling subjects with a clinical diagnosis…” / “patients… classified… based on serological status…”

⸻

[19] Diagnosis Criteria Details: NA
	•	Line(s): 30–34
	•	Section: Introduction
	•	Quote(s): “classified according to… age of onset… thymoma… phenotype…”

⸻

[20] Disease Phase: NR
	•	Line(s): 27–28
	•	Section: Abstract / Introduction
	•	Quote(s): “fluctuating course… characteristic fatigable weakness” → suggests both acute and chronic phases
(Note: explicitly stating “NR” if user prefers strict definitions)

⸻

[21] Cohort Age Group: Mixed
	•	Line(s): 255–273
	•	Section: Age and Sex Distribution
	•	Quote(s): “mean age… 53.7… juvenile MG… peak between 25 and 39 years…”

⸻

[22] Female % in Cohort: NA
	•	Line(s): 255
	•	Section: Age and Sex Distribution
	•	Quote(s): “a higher number of females was observed, with a ratio of F/M = 1.6/1”

⸻

[23] Consanguinity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR